tiprankstipranks
Trending News
More News >
Ramm Pharma Corp (TSE:RAMM)
:RAMM
Canadian Market

Ramm Pharma (RAMM) AI Stock Analysis

Compare
1 Followers

Top Page

TS

Ramm Pharma

(RAMM)

Rating:41Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
Ramm Pharma's stock is weighed down by significant financial struggles, including persistent net losses and negative cash flows. Technical analysis further reflects weak momentum and bearish market conditions. The valuation is unattractive due to a negative P/E ratio and absence of dividends. Strategic improvements in financial performance are essential to enhance stock value.

Ramm Pharma (RAMM) vs. iShares MSCI Canada ETF (EWC)

Ramm Pharma Business Overview & Revenue Model

Company DescriptionRamm Pharma (RAMM) is a pharmaceutical company that specializes in the development and commercialization of cannabinoid-based products. The company operates in the medical, pharmaceutical, and wellness sectors, offering a range of products that include prescription medications, over-the-counter treatments, and wellness supplements. Ramm Pharma focuses on leveraging its expertise in cannabinoid research to provide innovative solutions for various health conditions.
How the Company Makes MoneyRamm Pharma makes money primarily through the sale of its cannabinoid-based pharmaceutical and wellness products. The company's revenue streams include direct sales to healthcare providers, pharmacies, and distributors, as well as partnerships with other pharmaceutical companies for co-development and distribution agreements. Additionally, Ramm Pharma may generate income from licensing its proprietary formulations and technologies to other entities. Strategic partnerships and collaborations with research institutions and healthcare organizations also contribute to the company's earnings by expanding its market reach and product offerings.

Ramm Pharma Financial Statement Overview

Summary
Ramm Pharma faces significant financial challenges, characterized by persistent losses and negative cash flows. While the balance sheet reflects low leverage, operational inefficiencies and declining revenues pose risks to the company's financial health. Strategic improvements in cost management and revenue growth are critical for future sustainability.
Income Statement
30
Negative
Ramm Pharma has consistently reported negative net income, indicating ongoing profitability challenges. The net profit margin remains negative, and the company has faced declining revenues over the past periods. This highlights issues with cost control and revenue generation.
Balance Sheet
45
Neutral
The company's balance sheet shows a reasonable debt-to-equity ratio, suggesting a low level of financial leverage. However, the declining equity base and significant losses impact the overall stability. The equity ratio is high, reflecting a strong reliance on equity, but may deteriorate if losses continue.
Cash Flow
35
Negative
Operating cash flow is consistently negative, indicating challenges in generating cash from core operations. Free cash flow has also been negative, impacting the company's ability to invest or pay down debt. The free cash flow to net income ratio is concerning, as it suggests poor cash conversion.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.40M4.34M5.07M3.90M4.12M5.44M
Gross Profit1.44M1.76M381.82K530.50K-7.64K1.28M
EBITDA-14.13M-15.23M-6.30M-19.91M-6.36M-6.91M
Net Income-15.23M-16.50M-7.72M-20.96M-7.11M-7.43M
Balance Sheet
Total Assets15.55M16.75M32.30M39.31M59.71M37.17M
Cash, Cash Equivalents and Short-Term Investments480.44K814.04K5.12M9.77M17.16M28.01M
Total Debt197.69K188.31K405.14K683.70K32.16K100.43K
Total Liabilities3.12M3.11M2.84M3.72M3.32M1.34M
Stockholders Equity12.43M13.63M29.46M35.59M56.39M35.84M
Cash Flow
Free Cash Flow-3.10M-4.05M-4.45M-6.08M-4.25M-4.80M
Operating Cash Flow-3.04M-4.00M-4.34M-5.91M-3.82M-2.91M
Investing Cash Flow-132.71K-47.43K126.58K-1.15M-6.83M-1.56M
Financing Cash Flow-264.87K-258.23K-409.97K-353.77K-190.33K-2.91M

Ramm Pharma Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.01
Negative
100DMA
0.02
Negative
200DMA
0.02
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
0.21
Positive
STOCH
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RAMM, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 0.21 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RAMM.

Ramm Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
46
Neutral
C$194.71M-4.33-8.58%2.64%13.66%-0.73%
41
Neutral
C$1.19M-70.13%-10.69%-53.89%
39
Underperform
C$1.76M62.01%35.35%31.85%
29
Underperform
C$1.08M-405.57%-2291.11%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:RAMM
Ramm Pharma
0.01
-0.01
-50.00%
TSE:OVAT
Ovation Science
0.05
0.02
42.86%
TSE:PHRX
Pharmadrug
0.01
-0.01
-50.00%

Ramm Pharma Corporate Events

M&A TransactionsBusiness Operations and Strategy
RAMM Pharma Explores Sale of Italian Subsidiary Canapar
Neutral
Jan 21, 2025

RAMM Pharma Corp. is considering the sale of its subsidiary, Canapar Corp., and its facility in Italy as part of its strategy to streamline operations and focus on core businesses. This potential sale is aimed at enhancing shareholder value and ensuring long-term company sustainability. However, there is no guarantee that a sale will occur, and updates will be provided as the process progresses.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 07, 2025